Absci Corp. Announces Inducement Grant Under Nasdaq Listing Rule

Absci Corporation (Nasdaq: ABSI), a leader in the integration of artificial intelligence and drug development, has made headlines with its recent announcement regarding a significant inducement stock option grant. On March 3, 2025, the company disclosed that it had granted a non-statutory stock option to purchase a total of 162,800 shares of its common stock to a newly-hired non-executive employee. This strategic move is designed to attract top talent and is in accordance with the Nasdaq Listing Rule 5635(c)(4).

The stock option granted carries an exercise price of $3.42 per share, aligning with the closing price of Absci's common stock on the Nasdaq Global Select Market on the grant date. The award features a generous 10-year term and is structured to vest over four years. Specifically, 25% of the shares will vest and become exercisable on the one-year anniversary of the grant date, with the remaining 75% vesting in approximately equal monthly installments over the next three years. This gradual vesting schedule incentivizes the new employee to remain with Absci and contribute to the company's growth.

The decision to issue this inducement grant reflects Absci's commitment to building a robust workforce capable of driving innovation in the field of biologics. By aligning employee compensation with the company’s long-term success, Absci aims to foster a culture of loyalty and performance. The Compensation Committee of Absci’s Board of Directors has approved this grant as part of the company's 2023 Inducement Plan, underscoring the importance of attracting high-caliber professionals in a competitive industry.

Absci Corporation operates at the forefront of drug discovery, leveraging its Integrated Drug Creation™ platform to merge advanced AI technology with scalable laboratory techniques. This unique approach allows the company to expedite the drug development process, significantly reducing the time it takes to bring new therapeutics to market. Absci’s capacity to screen billions of cells weekly enables the transition from AI-designed drug candidates to wet lab-validated candidates in as little as six weeks, maximizing the probability of clinical success.

With headquarters located in Vancouver, Washington, and additional facilities in New York City and Zug, Switzerland, Absci is well-positioned to influence the future of drug development on a global scale.

Absci remains dedicated to maintaining open lines of communication with investors and the public. The company routinely shares updates through its website and various social media platforms, ensuring that stakeholders are informed of significant developments. This commitment to transparency reflects Absci's understanding of the vital role that investor relations play in fostering trust and support within the financial community.

As Absci continues to innovate in the realm of drug development, the recent inducement grant stands as a testament to its strategic focus on talent acquisition, positioning the company for future growth and success in the pharmaceutical landscape.